Actelion, Ltd. is a biopharmaceutical company focused on the discovery, development and commercialization of innovative drugs for diseases with significant unmet medical needs. They are one of the leaders in the science and medicine of pulmonary arterial hypertension (PAH), with over 15 years of experience.
Dr. Urs Lüthi leads a team that is performing high-throughput screenings to identify modulators of different target classes using state-of-the-art automation infrastructure and assay technologies. In one project, the team is combing the FLIPR® Potassium Assay Kit with the FLIPR Tetra® High-Throughput Cellular Screening System to explore the permeability of thallium fluxes through potassium channels and to compare the effects of channel blockers with patch-clamp technology. Urs says, “The sensitivity and reproducibility of this assay system is exceptional compared to other kits and technologies that we have tested in the last months”.
